1. Introduction {#sec1}
===============

Small cell ovarian carcinoma pulmonary type (SCOCPT) is defined as a small cell carcinoma that resembles a neuroendocrine type of pulmonary small cell carcinoma. Most patients with SCOCPT are postmenopausal and present with symptoms such as a pelvic or abdominal mass. SCOCPTs are highly aggressive neoplasms, which usually present at an advanced stage, and the overall prognosis is poor. Only 26 cases of SCOCPT have been reported in the literature, and most patients have typically been treated with surgery followed by chemotherapy. Palliative brain irradiation was administered to control seizures in the previous report \[[@B1]\], but the cytoreductive effect of radiotherapy on the primary lesions is unknown. Here we present a case in which a patient with chemotherapy-resistant SCOCPT underwent abdominal radiotherapy. We describe the outcomes of the radiotherapy and also present evidence on lactate dehydrogenase (LDH) potentially acting as a good tumor marker during the course of treatment.

2. Case Presentation {#sec2}
====================

A 45-year-old woman (gravida 1, para 1) presented at our hospital with abdominal swelling. She had undergone laser ablation of cervical intraepithelial neoplasia 3 (CIN3) 12 years previously. She had a family history of paternal prostate cancer. Physical examination showed a large solid tumor in her pelvic region. Abdominal magnetic resonance imaging (MRI) identified a unilateral ovarian mass and small ascites. The tumor, approximately 12 cm in diameter, revealed a mixed pattern of multicystic and solid parts. Uterine endometrial thickening was also observed, and endometrial biopsy revealed grade 1 endometrioid carcinoma. Computed tomography (CT) revealed no lymph node metastasis or extrapelvic tumors. The laboratory data showed an elevated level of LDH (1246 U/L, normal \< 210 U/L). Isozyme analysis results were as follows: LD1 15%, LD2 30%, LD3 27%, LD4 18%, and LD5 10%. The serum level of cancer antigen 125 (CA125) was 156.7 U/mL (normal \< 35 U/mL). The serum calcium level was normal. Double cancer of the ovary and endometrium was suspected, and a staging laparotomy was scheduled. Eighteen days after first consultation, the patient complained of severe abdominal pain, and ultrasonography revealed that the tumor had enlarged to 16 cm in diameter, with an accumulation of ascitic fluid and newly diagnosed peritoneal dissemination. The tumor was rapidly progressing, and tumor rupture was also suspected. She underwent an urgent laparotomy, which revealed that a white and solid tumor of the right ovary had spontaneously ruptured in the intra-abdominal cavity ([Figure 1(a)](#fig1){ref-type="fig"}). There was massive bloody ascites of approximately 2700 mL in volume. The tumor was strongly adherent to the bladder and sigmoid colon and was difficult to decorticate. Multiple, but small, peritoneal disseminations were observed in the pelvic cavity. Total abdominal hysterectomy, bilateral salpingo-oophorectomy, and partial omentectomy were performed, and a 5 × 4 cm tumor remained behind the bladder due to the strong adhesion. The pathological diagnosis was SCOCPT ([Figure 1(b)](#fig1){ref-type="fig"}) and grade 1 endometrioid carcinoma of the uterine corpus ([Figure 1(c)](#fig1){ref-type="fig"}). Immunostaining of the ovarian tumor was positive for epithelial membrane antigen, synaptophysin ([Figure 1(d)](#fig1){ref-type="fig"}), neuron-specific enolase (NSE) ([Figure 1(e)](#fig1){ref-type="fig"}), p16, and cluster of differentiation (CD) 56 and negative for cytokeratin 20, Wilms Tumor 1, thyroid transcription factor 1, and anti-cytokeratin (CK) antibodies CK18, CK19, and CD99. Thus, we diagnosed primary ovarian cancer stage IIIC (pT3cNxM0) and endometrial cancer stage IA (pT1aNxM0) according to the International Federation of Gynecology and Obstetrics classification system. The serum level of NSE after surgery was 28.1 ng/mL (normal \< 16.3 ng/mL).

Twenty days after surgery, a CT scan revealed that the remaining tumor in the pelvic cavity had enlarged to 14.8 cm. At 21 days after surgery, the patient received adjuvant chemotherapy combining cisplatin (60 mg/m^2^ on day 1) and etoposide (100 mg/m^2^ on days 1 to 3) administered every 3 weeks by intravenous infusion. After each course, CT scanning revealed slight shrinkage of the residual tumor, but it enlarged during the drug holidays. After 3 courses of this regimen, the tumor was observed to have enlarged to 20.3 cm on CT. The patient\'s performance status, as measured using the Eastern Cooperative Oncology Group (ECOG) grading scale, was grade 3, and she complained of abdominal swelling. Therefore, irradiation of the abdominal tumor was initiated. A total dose of 26 Gy was given in 13 fractions, and the tumor size decreased to 15.3 cm with improved symptoms ([Figure 2](#fig2){ref-type="fig"}). However, several hypointensity lesions suggestive of intratumor gas were observed in the pelvic tumor. The patient gradually felt severely fatigued and refused any treatment. She was transferred to a hospice and died 135 days after the surgery. An autopsy was not performed. During the course of treatment, serum LDH levels repeatedly decreased soon after the chemotherapy but increased during drug holidays ([Figure 3](#fig3){ref-type="fig"}).

3. Discussion {#sec3}
=============

We identified two important clinical issues. Palliative radiotherapy for SCOCPT can be considered in patients with abdominal swelling, and LDH is a useful tumor marker.

First, with regard to palliative radiotherapy as a cytoreductive effect for SCOCPT, a total of 26 cases of SCOCPT have been reported in the literature, and 18 of these were treated with chemotherapy postoperatively ([Table 1](#tab1){ref-type="table"}) \[[@B1]--[@B15]\]. To our knowledge, this is the first report of SCOCPT treated with radiotherapy except for brain irradiation to control seizures with brain metastasis. Palliative radiotherapy at a dose of 26 Gy for the residual abdominal tumor contributed to tumor shrinkage by approximately 25%. Intratumor gas was observed, but it was not ascertained that the fistula between the tumor and the intestines was attributable to radiotherapy. It is not clear if radiotherapy improved the prognosis. However, we believe that radiotherapy was at least effective for improving the symptoms associated with tumor enlargement.

There are many reports regarding the effectiveness of radiotherapy in small cell carcinoma in other organs. Radiotherapy plays a vital role in the management of the full spectrum of small cell lung cancer, from its ability to palliate symptoms to improvements in survival \[[@B16]\]. Thoracic radiotherapy combined with chemotherapy improves survival in patients with limited-stage small cell lung cancer \[[@B17], [@B18]\]. According to the National Comprehensive Cancer Network guideline, concurrent chemoradiotherapy (CCRT) is recommended for limited-stage small cell lung cancer in excess of T1-2 N0 \[[@B19]\]. According to reports on small cell carcinoma in other sex organs, including the uterine cervix, endometrium, and vagina, multimodality therapy is likely the treatment of choice \[[@B20]\]. Patients with SCOCPT never received pelvic or abdominal radiation in previous reports. It is reasonable to follow treatment trends for small cell carcinoma of the lung, since tumors are histologically indistinguishable and exhibit a similar aggressive behavior.

Second, with regard to LDH as a useful tumor marker of SCOCPT, CA125 (positive rate 82.4%), NSE (85.7%), and CA19-9 (37.5%) have been reported as tumor markers for SCOCPT \[[@B21]\], but LDH has not been reported. Increased LDH is a prognostic tumor marker in many other solid tumors, including non-small cell lung cancer \[[@B22]\], breast cancer \[[@B23]\], and prostate cancer \[[@B24]\]. It has long been known that many human cancers have higher LDH levels than normal tissues \[[@B25]\]. The serum level of LDH is thought to be correlated with the tumor burden and to reflect the tumor\'s growth and invasive potential \[[@B26]\]. In this case, chemotherapy and radiotherapy transiently inhibited the growth of both tumor cells and LDH production, which led to an acute decrease in the serum LDH level. Because of the highly proliferative capacity of SCOCPT, serum LDH levels increased during the drug holidays. Although LDH has five isoforms with different distributions, it was not necessary to detect these isoforms separately because no specific isoform was characteristically increased. This is useful, because total serum LDH assessment is convenient and inexpensive \[[@B27]\]. Serum LDH can be a useful tumor marker to evaluate the effectiveness of the treatment and to assess the prognosis.

4. Conclusion {#sec4}
=============

Palliative radiotherapy for SCOCPT can be considered in patients with abdominal swelling, and LDH might be a useful tumor marker. Radiotherapy might be considered as an option if the tumor is resistant to chemotherapy after a staging laparotomy. Furthermore, multimodality therapy might be appropriate in patients thought to be candidates for aggressive, potentially curative treatments, but further research is required to establish the treatment strategy for SCOCPT.
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![(a) Macroscopic findings: an irregular, white, and solid tumor of the right ovary. ((b)--(d)) Microscopic findings. (b) Tumor cells are round to ovoid with hyperchromatic nuclei, scant cytoplasm, abundant mitosis, and apoptosis with conspicuous necrosis (hematoxylin-eosin stain (HE), ×300). (c) Endometrial carcinoma grade 1 in uterine corpus (HE, ×30) with less than half myometrial invasion and no vascular invasion. ((d), (e)) Tumor cells are positive for synaptophysin and neuron-specific enolase (immunostaining, ×300).](CRIOG2018-4383216.001){#fig1}

![(a) Enhanced abdominal computed tomography (coronal section) reveals the remaining tumor is approximately 20.3 cm in diameter before irradiation. (b) After radiation therapy, the tumor size decreased to 15.3 cm.](CRIOG2018-4383216.002){#fig2}

![The graph shows the time course of the levels of serum lactate dehydrogenase (LDH), cancer antigen 125 (CA125), and neuron-specific enolase (NSE). The patient underwent surgery (S) on day 21; chemotherapy (C) on days 43, 65, and 86; and abdominal irradiation (R) from day 120 to day 140. She died on day 157 (D). The solid line shows levels of LDH, the dashed-line shows levels of CA125, and the dashed-dotted line shows levels of NSE.](CRIOG2018-4383216.003){#fig3}
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A review of the literature: the characteristics, the treatment, and the outcome of small cell ovarian carcinoma, pulmonary type.

  Author                              Year   Age                                                Stage                        Operation                                                                                Postoperative treatment   Outcome
  ----------------------------------- ------ -------------------------------------------------- ---------------------------- ---------------------------------------------------------------------------------------- ------------------------- -------------
  Eichhorn et al. \[[@B1]\]           1992   62                                                 1a                           RSO                                                                                      None                      DOD, 4 Mo
  59                                  1a     TAH, RSO                                           Unknown                      Unknown                                                                                                            
  55                                  1a     TAH, BSO                                           Unknown                      Unknown                                                                                                            
  28                                  1c     TAH, BSO, OMT, appendectomy, peritoneal biopsies   Unknown                      AWD, 6 Mo                                                                                                          
  85                                  2b     BSO                                                None                         DOD, 1 Mo                                                                                                          
  76                                  3b     BSO (subtotal resection)                           Unknown                      DOD, 12 Mo                                                                                                         
  50                                  3b     LSO                                                Unknown                      Unknown                                                                                                            
  72                                  3b     TAH, BSO, OMT                                      CDDP, CPM                    DOD, 12 Mo                                                                                                         
  64                                  3b     TAH, BSO, OMT, LND, colectomy, appendectomy        CDDP, CPM, ADR               AWD, 8 Mo                                                                                                          
  49                                  3b     LSO, ileocolectomy, right para-aortic LND          CDDP, CPM, ADR, MTX, 5-FU    DOD, 13 Mo                                                                                                         
  46                                  3c     TAH, BSO, retroperitoneal LND                      CDDP, CPM, ADR, VP-16, VCR   ANED, 7.5 years                                                                                                    
                                                                                                                                                                                                                                                
  Chang et al. \[[@B2]\]              1992   22                                                 1a                           LSO, enucleation of the right ovarian tumor                                              CDDP, CPM, ADR            ANED, 84 Mo
                                                                                                                                                                                                                                                
  Fukunaga et al. \[[@B3]\]           1997   64                                                 1a                           TAH, BSO, OMT, pelvic and para-aortic LND                                                CDDP, CPM                 DOD, 10 Mo
                                                                                                                                                                                                                                                
  Lim et al. \[[@B4]\]                1998   28                                                 4b                           TAH, BSO                                                                                 CDDP, VP-16, BLM          ANED, 34 Mo
                                                                                                                                                                                                                                                
  Mebis et al. \[[@B5]\]              2004   54                                                 3c                           TAH, BSO, OMT                                                                            CDDP, IFM, VP-16          DOD, 14 Mo
                                                                                                                                                                                                                                                
  Rund and Fischer \[[@B6]\]          2006   56                                                 3c                           TAH, BSO, OMT, pelvic LND, splenectomy, segmental resection of ileum and sigmoid colon   CDDP, VP-16               AWD, 7 Mo
  2006                                39     3a                                                 TAH, BSO, OMT                CDDP, VP-16, PTX                                                                         DOD, 16 Mo                
                                                                                                                                                                                                                                                
  Grandjean et al. \[[@B7]\]          2007   32                                                 1a                           BSO, OMT, left pelvic LND                                                                CDDP, VP-16               ANED
                                                                                                                                                                                                                                                
  Saitoh-Sekiguchi et al. \[[@B8]\]   2007   55                                                 3c                           TAH, BSO, OMT, cytoreductive surgery of dissemination                                    CDDP, CPT-11              ANED, 12 Mo
                                                                                                                                                                                                                                                
  Suzuki et al. \[[@B9]\]             2007   49                                                 1c(a)                        TAH, BSO, pelvic and para-aortic LND, OMT                                                CBDCA, PTX                ANED, 36 Mo
                                                                                                                                                                                                                                                
  Reckova et al. \[[@B10]\]           2010   67                                                 4b                           TAH, BSO, OMT, appendectomy                                                              CBDCA, VP-16              DOD, 24 Mo
                                                                                                                                                                                                                                                
  Ikota et al. \[[@B11]\]             2012   68                                                 1a                           TAH, BSO, OMT                                                                            None                      ANED, 10 Mo
                                                                                                                                                                                                                                                
  Kira et al. \[[@B12]\]              2012   33                                                 3c                           TAH, BSO, OMT, pelvic and para-aortic LND                                                CDDP, CPT-11              DOD, 6 Mo
                                                                                                                                                                                                                                                
  Tsolakidis et al. \[[@B13]\]        2012   55                                                 3c                           TAH, BSO, OMT, sigmoidectomy, pelvic and para-aortic LND                                 CBDCA, VP-16              AEND, 21 Mo
                                                                                                                                                                                                                                                
  Kurasaki et al. \[[@B14]\]          2013   54                                                 3a                           TAH, BSO, OMT                                                                            CBDCA, PTX                ANED, 22 Mo
                                                                                                                                                                                                                                                
  Rubio et al. \[[@B15]\]             2015   37                                                 3b                           TAH, BSO, OMT, pelvic LND                                                                CDDP, VP-16               DOD, 4 Mo

TAH, total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy; LND, lymph node dissection; OMT, omentectomy; CDDP, cisplatin; CBDCA, carboplatin; PTX, paclitaxel; ADR, doxorubicin; CPM, cyclophosphamide; VP-16, etoposide; CPT-11, irinotecan; IFM, ifosfamide; BLM, bleomycin; VCR, vincristine; MTX, methotrexate; 5-FU, 5-fluorouracil; DOD, dead of disease; ANED, alive with no evidence of disease; AWD, alive with recurrent or residual disease; Mo, months.
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